Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-17 00:05 | 2025-10-16 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $60.03 | 5,000 | $300,150 | 363,108 |
| 2025-10-16 01:00 | 2025-10-13 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer | OPT+S | $18.88 | 24,734 | $466,936 | 309,892 |
| 2025-10-15 23:30 | 2025-10-13 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $87.36 | 40,000 | $3,494,304 | 61,734 |
| 2025-10-15 23:30 | 2025-10-13 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Officer | OPT+S | $88.84 | 10,070 | $894,578 | 65,963 |
| 2025-10-15 23:36 | 2025-10-13 | LQDA | Liquidia Corp | Schundler Russell | Officer | OPT+S | $23.41 | 7,839 | $183,511 | 576,017 |
| 2025-10-15 23:34 | 2025-10-13 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $23.41 | 4,900 | $114,709 | 153,462 |
| 2025-10-15 23:33 | 2025-10-13 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | OPT+S | $23.41 | 5,327 | $124,705 | 247,930 |
| 2025-10-15 23:32 | 2025-10-13 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $23.41 | 1,238 | $28,982 | 185,411 |
| 2025-10-15 23:30 | 2025-10-13 | LQDA | Liquidia Corp | Krepp Sarah | Officer | SELL | $23.41 | 1,691 | $39,586 | 141,439 |
| 2025-10-15 23:31 | 2025-10-13 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $23.41 | 3,670 | $85,915 | 175,690 |
| 2025-10-15 23:34 | 2025-10-13 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $23.41 | 11,630 | $272,258 | 352,646 |
| 2025-10-16 02:04 | 2025-10-13 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | Officer | SELL | $42.01 | 10,758 | $451,983 | 116,865 |
| 2025-10-16 02:04 | 2025-10-15 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | SELL | $43.01 | 10,369 | $445,982 | 71,155 |
| 2025-10-15 20:24 | 2025-10-15 | KROS | Keros Therapeutics, Inc. | ADAR1 Capital Management, LLC | 10% owner | SELL | $17.75 | 5,389,264 | $95,659,436 | 0 |
| 2025-10-16 02:04 | 2025-10-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer | SELL | $42.67 | 15,100 | $644,328 | 831,305 |
| 2025-10-16 01:47 | 2025-10-15 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $31.53 | 9,000 | $283,776 | 73,740 |
| 2025-10-16 03:12 | 2025-10-10 | APLS | Apellis Pharmaceuticals Inc. | Dunlop A. Sinclair | Director | SELL | $23.72 | 31,092 | $737,536 | 3,837 |
| 2025-10-16 03:07 | 2025-10-13 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.68 | 153,816 | $259,165 | 1,650,204 |
| 2025-10-16 01:33 | 2025-10-10 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Director | SELL | $30.47 | 194,932 | $5,939,792 | 751,664 |
| 2025-10-16 00:15 | 2025-10-14 | QNRX | Quoin Pharmaceuticals, Ltd. | LANGER DENNIS | Director | BUY | $8.49 | 15,152 | $128,640 | 15,153 |
| 2025-10-15 23:31 | 2025-10-13 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | OPT+S | $23.41 | 20,261 | $474,310 | 1,032,973 |
| 2025-10-16 01:31 | 2025-10-10 | CORT | CORCEPT THERAPEUTICS INC | Swisher Daniel N JR | Director | OPT+S | $87.54 | 2,200 | $192,588 | 0 |
| 2025-10-15 23:30 | 2025-10-13 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $440.35 | 22,500 | $9,907,963 | 0 |
| 2025-10-15 23:30 | 2025-10-13 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $438.95 | 8,000 | $3,511,604 | 130 |
| 2025-10-14 23:00 | 2025-10-10 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $863.24 | 3,658 | $3,157,722 | 94,533,320 |
| 2025-10-15 03:11 | 2025-10-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Director, Officer | OPT+S | $53.98 | 30,000 | $1,619,340 | 526,114 |
| 2025-10-15 04:00 | 2025-10-09 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $16.29 | 125,667 | $2,047,342 | 1,504,959 |
| 2025-10-15 00:14 | 2025-10-09 | ZBIO | Zenas BioPharma, Inc. | SR ONE CAPITAL MANAGEMENT, LLC | 10% owner | BUY | $19.00 | 126,315 | $2,399,985 | 1,917,895 |
| 2025-10-14 23:31 | 2025-10-09 | VSTM | Verastem, Inc. | Bunn Paul A. | Director | SELL | $9.06 | 8,333 | $75,497 | 8,333 |
| 2025-10-14 19:15 | 2025-10-13 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer | SELL | $31.51 | 7,942 | $250,252 | 98,227 |
| 2025-10-15 00:16 | 2025-10-09 | ZBIO | Zenas BioPharma, Inc. | Nunn Jason Raleigh | Director | BUY | $19.00 | 63,158 | $1,200,002 | 1,173,395 |
| 2025-10-14 23:05 | 2025-10-09 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $14.09 | 3,600 | $50,706 | 198,533 |
| 2025-10-14 23:05 | 2025-10-09 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | Officer | SELL | $14.03 | 3,493 | $49,011 | 13,533 |
| 2025-10-14 23:01 | 2025-10-10 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Director | OPT+S | $81.62 | 12,000 | $979,480 | 5,130 |
| 2025-10-14 20:16 | 2025-10-13 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $5.20 | 4,326 | $22,495 | 0 |
| 2025-10-14 15:59 | 2025-10-09 | ZBIO | Zenas BioPharma, Inc. | ENRIGHT PATRICK G | Director | BUY | $19.19 | 117,255 | $2,250,030 | 11,990 |
| 2025-10-15 01:00 | 2025-10-10 | BGMS | Bio Green Med Solution, Inc. | FITTERS Diversified Berhad | 10% owner | SELL | $5.26 | 51,400 | $270,261 | 505,758 |
| 2025-10-15 02:49 | 2025-10-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $90.09 | 400 | $36,036 | 75,674 |
| 2025-10-10 23:00 | 2025-10-09 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $852.49 | 10,602 | $9,038,056 | 94,536,978 |
| 2025-10-11 00:23 | 2025-10-09 | BCAX | Bicara Therapeutics Inc. | Raben David | Officer | OPT+S | $18.45 | 22,000 | $405,900 | 35,497 |
| 2025-10-11 00:22 | 2025-10-09 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer | OPT+S | $18.23 | 6,415 | $116,931 | 145,355 |
| 2025-10-11 00:40 | 2025-10-08 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $54.79 | 80,000 | $4,383,440 | 835,686 |
| 2025-10-10 23:56 | 2025-10-08 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | OPT+S | $350.40 | 10,671 | $3,739,108 | 0 |
| 2025-10-10 23:12 | 2025-10-08 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. MD | Director | OPT+S | $30.00 | 25,000 | $750,000 | 49,124 |
| 2025-10-11 00:58 | 2025-10-08 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.78 | 13,876 | $24,720 | 1,804,020 |
| 2025-10-10 23:18 | 2025-10-08 | AGIO | Agios Pharmaceuticals Inc. | Scadden David | Director | OPT+S | $41.00 | 200 | $8,200 | 17,603 |
| 2025-10-11 02:17 | 2025-10-10 | ZVRA | ZEVRA THERAPEUTICS, INC. | McFarlane Neil F. | Director, Officer | OPT+S | $10.82 | 19,500 | $210,908 | 222,016 |
| 2025-10-10 23:01 | 2025-10-08 | OCUL | OCULAR THERAPEUTIX, INC | Anderman Todd | Officer | SELL | $12.34 | 11,132 | $137,369 | 87,568 |
| 2025-10-11 00:33 | 2025-10-09 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $50.57 | 59,900 | $3,029,335 | 1,206,578 |
| 2025-10-10 23:30 | 2025-10-08 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director | SELL | $2.42 | 121,791 | $294,552 | 8,260 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.